Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia

Annals of Oncology

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Williams, M E ^a,c   Whitefield, M ^a   Swerdlow, S H ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

CDKI; Cell cycle; Cyclin D1; Non Hodgkin's lymphoma; P15 MTS2; P16 MTS1; P53

Indexed keywords

CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; PREDNISONE; PROTEIN P16; PROTEIN P53; VINCRISTINE SULFATE;

ADULT; AGED; AUTORADIOGRAPHY; BIOPSY; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE DELETION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; POINT MUTATION; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0030751625     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_2.S71     Document Type: Conference Paper

References (14)

1. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82.
2. Sherr C. G1 phase progression: Cycling on cue. Cell 1994; 79: 551-6.
3. Swerdlow SH, Yang WI, Zukerberg LR et al. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol 1995; 26: 999-1004.
4. Zukerberg LR, Yang WI, Arnold A et al. Cyclin D1 expression in non-Hodgkin's lymphomas: Detection by immunohistochemistry. Am J Clin Pathol 1995; 103: 756-60.
5. Williams ME, Swerdlow SH. Rosenberg CL et al. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992; 52: 5541-4.
6. Louie DC, Offit K, Jaslow R et al. P53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 1995; 86: 2892-9.
7. Hernandez L, Fest T, Cazorla M et al. P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351-9.
8. Greiner T, Moynihan MJ, Chan WC et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302-10.
9. INK4B/MTS2-related CDR6 inhibitor, Correlates with wild-type pRb function. Genes Devel 1994; 8: 2939-52.
10. Hirai H, Roussel MF, Kato JY et al. Novel INK4 proteins. p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-81.
11. Leroux D, Le Marc'Hadour F, Gressin R et al. Non-Hodgkin's lymphomas with t(11;14)(q13;q32): A subset of mantle zone/intermediate lymphocytic lymphoma? Br J Haematol 1991; 77: 346-53.
12. ink4. Mol Cell Biol 1995; 15: 2682-8.
13. 1NK4c in tumor-derived cell lines and primary tumors. Oncogene 1996; 12: 451-5.
14. Galiegue-Zouitina S, Collyn-d'Hooghe M, Denis C et al. Molecular cloning of a t(11;14)(q13;q32) translocation breakpoint centromeric to the BCL1-MTC. Genes Chrom Cancer 1994; 11: 246-55.